Avanos Medical, Inc. (AVNS) Financial Ratios
14 years of historical data (2012–2025) · Healthcare · Medical - Devices
EV/EBITDA
↓
N/A
—
5yr avg: 12.82
30Y Low6.6·High54.7
P/FCF
↓
26.77
-1% vs avg
5yr avg: 27.16
30Y Low8.8·High71.6
P/B Ratio
↓
1.47
↑+56% vs avg
5yr avg: 0.94
30Y Low0.7·High1.8
ROE
↓
-8.5%
↓+10% vs avg
5yr avg: -9.4%
30Y Low-38%·High7%
Debt/EBITDA
↑
N/A
—
5yr avg: 2.19
30Y Low0.0·High24.2
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
AVNS Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Avanos Medical, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis. On a free-cash-flow basis, the stock trades at 26.8x P/FCF, roughly in line with the 5-year average of 27.2x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.2B | $521M | $732M | $1.0B | $1.3B | $1.7B | $2.2B | $1.6B | $2.1B | $2.2B | $1.7B |
| Enterprise Value | $1.2B | $560M | $795M | $1.2B | $1.4B | $1.8B | $2.3B | $1.7B | $2.0B | $2.5B | $2.2B |
| P/E Ratio → | -16.93 | — | — | — | 25.29 | 266.69 | — | — | 36.71 | 27.33 | 43.51 |
| P/S Ratio | 1.65 | 0.74 | 1.06 | 1.55 | 1.87 | 2.26 | 3.07 | 2.30 | 3.24 | 3.53 | 3.07 |
| P/B Ratio | 1.47 | 0.67 | 0.88 | 0.85 | 0.99 | 1.33 | 1.75 | 1.27 | 1.63 | 1.78 | 1.58 |
| P/FCF | 26.77 | 12.09 | 8.83 | 71.59 | 17.88 | 25.41 | — | — | — | 21.40 | 10.88 |
| P/OCF | 15.45 | 6.98 | 7.27 | 32.26 | 14.08 | 19.30 | — | — | — | 14.99 | 9.21 |
P/E links to full P/E history page with 30-year chart
AVNS EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.80 | 1.16 | 1.73 | 2.09 | 2.36 | 3.26 | 2.47 | 3.03 | 4.12 | 3.89 |
| EV / EBITDA | — | — | 9.30 | 10.75 | 17.22 | 14.02 | 20.48 | 54.74 | 28.91 | 105.10 | — |
| EV / EBIT | — | — | — | 164.32 | 38.94 | 165.47 | — | — | 564.94 | — | — |
| EV / FCF | — | 13.00 | 9.59 | 79.91 | 19.96 | 26.45 | — | — | — | 24.97 | 13.80 |
AVNS Profitability
Margins and return-on-capital ratios measuring operating efficiency
Avanos Medical, Inc. earns an operating margin of -8.8%. Operating margins have compressed from 9.7% to -8.8% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -8.5% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 49.8% | 49.8% | 55.4% | 56.4% | 57.6% | 51.0% | 54.6% | 57.7% | 59.9% | 55.1% | 52.5% |
| Operating Margin | -8.8% | -8.8% | 5.8% | 9.7% | 6.1% | 11.7% | 9.9% | -0.8% | 5.4% | -2.6% | -12.3% |
| Net Profit Margin | -9.7% | -9.7% | -57.0% | -9.2% | 7.4% | 0.8% | -3.8% | -6.6% | 8.8% | 13.0% | 7.0% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -8.5% | -8.5% | -38.0% | -4.9% | 3.9% | 0.5% | -2.2% | -3.6% | 4.6% | 6.8% | 3.7% |
| ROA | -6.1% | -6.1% | -27.5% | -3.6% | 3.0% | 0.4% | -1.6% | -2.5% | 2.9% | 3.7% | 2.0% |
| ROIC | -5.4% | -5.4% | 2.7% | 3.5% | 2.3% | 4.8% | 3.8% | -0.3% | 1.9% | -0.8% | -3.4% |
| ROCE | -6.5% | -6.5% | 3.3% | 4.3% | 2.7% | 5.8% | 4.6% | -0.3% | 2.1% | -0.9% | -4.0% |
AVNS Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $39M ($129M total debt minus $90M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.17 | 0.17 | 0.21 | 0.17 | 0.21 | 0.15 | 0.20 | 0.26 | 0.19 | 0.48 | 0.53 |
| Debt / EBITDA | — | — | 1.99 | 1.93 | 3.34 | 1.50 | 2.19 | 10.33 | 3.62 | 24.20 | — |
| Net Debt / Equity | — | 0.05 | 0.08 | 0.10 | 0.12 | 0.05 | 0.11 | 0.09 | -0.11 | 0.30 | 0.42 |
| Net Debt / EBITDA | — | — | 0.73 | 1.12 | 1.80 | 0.55 | 1.21 | 3.81 | -2.00 | 15.05 | — |
| Debt / FCF | — | 0.91 | 0.75 | 8.32 | 2.09 | 1.04 | — | — | — | 3.58 | 2.91 |
| Interest Coverage | -15.55 | -15.55 | -32.06 | 0.47 | 3.67 | 3.21 | -2.88 | -3.27 | 0.13 | -1.28 | -3.26 |
AVNS Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Avanos Medical, Inc.'s current ratio of 2.15x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 1.26x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 2.08x to 2.15x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.15 | 2.15 | 2.37 | 2.08 | 3.27 | 3.07 | 2.81 | 2.53 | 2.70 | 2.98 | 1.83 |
| Quick Ratio | 1.26 | 1.26 | 1.53 | 1.38 | 2.57 | 1.93 | 1.79 | 1.85 | 2.24 | 2.74 | 0.99 |
| Cash Ratio | 0.54 | 0.54 | 0.65 | 0.37 | 0.67 | 0.85 | 0.67 | 0.97 | 1.45 | 0.56 | 0.35 |
| Asset Turnover | — | 0.65 | 0.60 | 0.40 | 0.38 | 0.46 | 0.43 | 0.39 | 0.36 | 0.28 | 0.27 |
| Inventory Turnover | 2.38 | 2.38 | 2.21 | 1.80 | 2.19 | 2.29 | 1.92 | 2.02 | 2.15 | 3.02 | 0.99 |
| Days Sales Outstanding | — | 54.03 | 70.47 | 77.41 | 89.58 | 64.31 | 85.74 | 85.70 | 84.21 | 121.15 | 121.52 |
AVNS Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Avanos Medical, Inc. returns 0.3% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | 4.0% | 0.4% | — | — | 2.7% | 3.7% | 2.3% |
| FCF Yield | 3.7% | 8.3% | 11.3% | 1.4% | 5.6% | 3.9% | — | — | — | 4.7% | 9.2% |
| Buyback Yield | 0.3% | 0.6% | 1.7% | 1.8% | 3.6% | 0.7% | 0.0% | 0.2% | 0.0% | 0.1% | 0.1% |
| Total Shareholder Yield | 0.3% | 0.6% | 1.7% | 1.8% | 3.6% | 0.7% | 0.0% | 0.2% | 0.0% | 0.1% | 0.1% |
| Shares Outstanding | — | $46M | $46M | $47M | $47M | $49M | $48M | $48M | $47M | $47M | $47M |
Peer Comparison
Compare AVNS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 AVNSYou | $1B | -16.9 | — | 26.8 | 49.8% | -8.8% | -8.5% | -5.4% | — |
 MMSI | $4B | 28.9 | 12.9 | 17.0 | 48.7% | 12.2% | 8.7% | 7.2% | 2.8 |
 NVCR | $2B | -13.5 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 ITGR | $3B | 29.9 | 13.0 | 28.2 | 23.1% | 11.3% | 6.1% | 5.4% | 4.2 |
 ATRC | $1B | -116.7 | 78.4 | 29.4 | 74.4% | -0.6% | -2.4% | -0.6% | 5.2 |
 NTRA | $30B | -140.6 | — | 427.2 | 60.3% | -13.1% | -19.4% | -33.3% | — |
 HOLX | $17B | 30.5 | 17.4 | 18.4 | 61.0% | 17.4% | 11.1% | 9.4% | 2.6 |
 ICUI | $3B | 3986.3 | 91.7 | 32.2 | 36.8% | 1.9% | 0.3% | 1.0% | 30.0 |
 ANGO | $459M | -13.3 | — | — | 53.9% | -13.7% | -17.5% | -22.9% | — |
 INVA | $2B | 6.8 | 8.0 | 9.8 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 MDT | $99B | 21.5 | 14.3 | 19.2 | 65.3% | 17.8% | 9.4% | 6.0% | 3.2 |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 14 years · Updated daily
See AVNS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AVNS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare AVNS vs MMSI
Side-by-side business, growth, and profitability comparison vs Merit Medical Systems, Inc..
Start ComparisonAVNS — Frequently Asked Questions
Quick answers to the most common questions about buying AVNS stock.
What is Avanos Medical, Inc.'s P/E ratio?
Avanos Medical, Inc.'s current P/E ratio is -16.9x. The historical average is 42.2x.
What is Avanos Medical, Inc.'s ROE?
Avanos Medical, Inc.'s return on equity (ROE) is -8.5%. The historical average is -3.9%.
Is AVNS stock overvalued?
Based on historical data, Avanos Medical, Inc. is trading at a P/E of -16.9x. Compare with industry peers and growth rates for a complete picture.
What are Avanos Medical, Inc.'s profit margins?
Avanos Medical, Inc. has 49.8% gross margin and -8.8% operating margin.